55 research outputs found
Caenorhabditis elegans BAH-1 Is a DUF23 Protein Expressed in Seam Cells and Required for Microbial Biofilm Binding to the Cuticle
The cuticle of Caenorhabditis elegans, a complex, multi-layered extracellular matrix, is a major interface between the animal and its environment. Biofilms produced by the bacterial genus Yersinia attach to the cuticle of the worm, providing an assay for surface characteristics. A C. elegans gene required for biofilm attachment, bah-1, encodes a protein containing the domain of unknown function DUF23. The DUF23 domain is found in 61 predicted proteins in C. elegans, which can be divided into three distinct phylogenetic clades. bah-1 is expressed in seam cells, which are among the hypodermal cells that synthesize the cuticle, and is regulated by a TGF-β signaling pathway
High growth rate of benign thyroid nodules bearing RET/PTC rearrangements.
CONTEXT:
Benign thyroid nodules display a broad range of behaviors from a stationary size to a progressive growth. The RET/PTC oncogene has been documented in a fraction of benign thyroid nodules, besides papillary thyroid carcinomas, and it might therefore influence their growth.
OBJECTIVE:
The aim of the present work was to evaluate whether RET/PTC in benign thyroid nodules associates with a different nodular growth rate.
STUDY DESIGN:
In this prospective multicentric study, 125 subjects with benign nodules were included. RET rearrangements were analyzed in cytology samples; clinical and ultrasonographic nodule characteristics were assessed at the start and at the end of the study.
RESULTS:
RET/PTC was present in 19 nodules. The difference between the mean baseline nodular volume of the RET/PTC- and RET/PTC+ nodules was not significant. After 36 months of follow-up, the RET/PTC+ group (n = 16) reached a volume higher than the RET/PTC- group (n = 90) (5.04 ± 2.67 vs. 3.04 ± 2.26 ml; P = 0.0028). We calculated the monthly change of nodule volumes as a percentage of baseline. After a mean follow-up of 36.6 months, the monthly volume increase of nodules bearing a RET rearrangement was 4.3-fold that of nodules with wild-type RET (1.83 ± 1.2 vs. 0.43 ± 1.0% of baseline volume; P < 0.0001)
The Primary Occurrence of BRAFV600E Is a Rare Clonal Event in Papillary Thyroid Carcinoma.
Context: BRAF V600E is considered a primary event, a negative prognostic marker, and a site for
pharmacological intervention in papillary thyroid carcinoma (PTC). We asked whether BRAF V600E
can occur as a subclonal event in PTC and whether this and other oncogenes can coexist in the same
tumor.
Study Design: We determined by pyrosequencing the percentage of mutant BRAF, NRAS, and
KRAS alleles in a series of conventional PTC. We also analyzed the BRAF mutation status in PTC cell
clones in culture.
Results: BRAF V600E alleles were present in 41 of 72 PTC (56.9%) in the range 44.7 to 5.1% of total
BRAF alleles. In four PTC samples, mutant BRAF alleles were about 50%, being therefore compat-
ible with a clonal heterozygous mutation. In 27 PTC samples, BRAF V600E alleles were in the range
of 25 to 5.1%. This finding was confirmed after exclusion of the presence of a large contamination
by lymphoreticular cells and by the analysis of PTC cells selected by laser capture. Analysis of clones
derived from a single cell confirmed the presence of two distinct PTC populations with wild-type
or mutated BRAF. Simultaneous subclonal BRAF and KRAS mutations were demonstrated in two
PTC.
Conclusions: These data demonstrate that clonal BRAF V600E is a rare occurrence in PTC, although
frequently this cancer consists of a mixture of tumor cells with wild-type and mutant BRAF. These
results suggest that BRAF mutation in PTC is a later subclonal event, its intratumoral heterogeneity
may hamper the efficacy of targeted pharmacotherapy, and its association with a more aggressive
disease should be reevaluated
- …